Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO ® (omalizumab-igec) as the first and only biosimilar designated as interchangeable with XOLAIR ® (omalizumab) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback